<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Opportunities span cell therapy, transplant expansion, standardized collection, digital traceability, AI-enabled workflows, workforce training and broader regional access.<div style="float:right;padding:0 0 15px 20px;margin:15px 0 20px 20px;width:300px">
 Leukapheresis Market
 <figure>
 <img src="https://ml.globenewswire.com/Resource/Download/a78aec95-7302-42c1-aa75-ea413510fdc5" title="Leukapheresis Market" alt="Leukapheresis Market" />
 <figcaption>Leukapheresis Market</figcaption>
 </figure>
</div>Dublin, July 21, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/report/leukapheresis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=8jz2jc&amp;utm_campaign=2308736+-+Global+Leukapheresis+Market+Growth+Accelerates+With+Cell+Therapy%2c+Oncology+and+Transplant+Demand&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Leukapheresis Market - Global Forecast 2026-2032">"Leukapheresis Market - Global Forecast 2026-2032"</a> has been added to ResearchAndMarkets.com's offering. <img alt="" height="400" src="//www.researchandmarkets.com/content-images/2526/2526601/1/leukapheresis-market.png" width="600" /> The global leukapheresis market research report provides an in-depth assessment of the clinical, technological, regulatory, and regional factors shaping this essential blood separation field. The market is projected to reach USD 169.10 million in 2026 and expand at a CAGR of 11.79% to USD 330.60 million by 2032. The analysis supports strategic planning by highlighting growth opportunities, operational requirements, and risks across hematology, transfusion medicine, transplantation, cellular therapy manufacturing, and immune-based research. Market Scope and Growth Drivers Leukapheresis selectively collects or reduces white blood cells and supports stem cell collection, mononuclear cell procurement, leukocyte depletion, and therapeutic management of selected conditions. Market growth is closely linked to expanding oncology and transplant programs, rising adoption of cell-based therapies, and demand for standardized, traceable starting materials. Stakeholders are prioritizing validated collection protocols, trained personnel, infection control, donor eligibility screening, vascular access planning, anticoagulation management, and digital documentation. These capabilities are critical for protecting patients, preserving product integrity, and maintaining reliable advanced therapy workflows. Transformative Market Shifts Leukapheresis is evolving from procedure-focused blood component collection into an integrated component of advanced therapy supply chains. The consistency of collected material can directly influence downstream processing, cell viability, potency testing, and manufacturing timelines. Clinical sites, processing laboratories, and logistics providers are coordinating vein-to-vein workflows involving precise scheduling, cryopreservation readiness, controlled transport, and chain-of-identity protection. The market is moving toward quality-by-design programs that connect clinical outcomes, manufacturing performance, compliance, and operational efficiency. Artificial Intelligence and Digital Integration Artificial intelligence is emerging as a decision-support tool for scheduling, predictive quality analytics, patient risk stratification, and manufacturing data integration. AI-enabled systems can align patient readiness, staff availability, device utilization, laboratory capacity, and logistics windows. Machine learning may also identify relationships among baseline cell counts, processed blood volume, anticoagulant ratios, procedure duration, and final yield. Automated anomaly detection can flag documentation errors, temperature deviations, and chain-of-custody issues. Adoption requires validated algorithms, cybersecurity controls, privacy safeguards, transparent performance, and continued clinician oversight. Regional and Country Insights North America remains a mature market, supported by advanced hematology-oncology networks, clinical trials, accredited apheresis centers, and cellular therapy manufacturing. Europe benefits from established blood systems, transplant registries, quality governance, and advanced therapy oversight. Asia-Pacific is expanding rapidly through oncology investment, transplant services, biotechnology development, and cell therapy research in China, Japan, India, South Korea, and Australia. Latin America is led by Brazil and Mexico, although reimbursement and urban infrastructure concentration affect access. Gulf countries are investing in tertiary care and transplant capabilities, while access across Africa remains concentrated in higher-resource medical centers. Country-level analysis enables organizations to compare regulatory readiness, infrastructure maturity, workforce availability, and market entry conditions. These insights can guide geographic prioritization and reduce expansion risks. Strategic Recommendations Industry leaders should: . Standardize collection protocols, acceptance criteria, labeling, transport, and anticoagulation practices. . Invest in training for clinicians, nurses, laboratory teams, quality personnel, and logistics coordinators. . Integrate medical records, device data, laboratory systems, and chain-of-custody platforms. . Strengthen supplier qualification, maintenance, temperature monitoring, and contingency planning. . Expand access through hub-and-spoke models, regional training, teleconsultation, and accredited hospital partnerships. These priorities provide a practical framework for improving collection reliability, audit readiness, manufacturing compatibility, and competitive positioning. Key Takeaways from This Report . The market is forecast to grow from USD 169.10 million in 2026 to USD 330.60 million by 2032. . Cell therapy adoption, transplant expansion, and demand for traceable starting materials are central growth drivers. . Standardization, workforce expertise, digital traceability, and supply chain coordination are critical success factors. . AI offers opportunities in scheduling, quality monitoring, and process consistency when implemented under validated controls. . Regional readiness varies significantly, creating distinct opportunities for investment, partnerships, and market entry. Key Attributes: <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Report Attribute</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">Details</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">No. of Pages</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">186</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecast Period</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">2026 - 2032</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Estimated Market Value (USD) in 2026</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$169.1 Million</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecasted Market Value (USD) by 2032</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$330.6 Million</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Compound Annual Growth Rate</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">11.7%</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">Regions Covered</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">Global</td></tr></table> Key Topics Covered: 1. Preface 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Segmentation &amp; Coverage 1.4. Years Considered for the Study 1.5. Currency Considered for the Study 1.6. Language Considered for the Study 1.7. Key Stakeholders 2. Research Methodology 2.1. Introduction 2.2. Research Design 2.2.1. Primary Research 2.2.2. Secondary Research 2.3. Research Framework 2.3.1. Qualitative Analysis 2.3.2. Quantitative Analysis 2.4. Market Size Estimation 2.4.1. Top-Down Approach 2.4.2. Bottom-Up Approach 2.5. Data Triangulation 2.6. Research Outcomes 2.7. Research Assumptions 2.8. Research Limitations 3. Executive Summary 3.1. Introduction 3.2. CXO Perspective 3.3. Market Size &amp; Growth Trends 3.4. New Revenue Opportunities 3.5. Next-Generation Business Models 3.6. Industry Roadmap 4. Market Overview 4.1. Introduction 4.2. Industry Ecosystem &amp; Value Chain Analysis 4.2.1. Supply-Side Analysis 4.2.2. Demand-Side Analysis 4.2.3. Stakeholder Analysis 4.3. Market Dynamics 4.3.1. Key Drivers 4.3.2. Key Restraints 4.3.3. Key Opportunities 4.3.4. Key Challenges 4.4. Porter's Five Forces Analysis 4.5. PESTLE Analysis 4.6. Market Outlook 4.6.1. Near-Term Market Outlook (0-2 Years) 4.6.2. Medium-Term Market Outlook (3-5 Years) 4.6.3. Long-Term Market Outlook (5-10 Years) 4.7. Go-to-Market Strategy 5. Market Insights 5.1. Consumer Insights &amp; End-User Perspective 5.2. Consumer Experience Benchmarking 5.3. Opportunity Mapping 5.4. Distribution Channel Analysis 5.5. Pricing Trend Analysis 5.6. Regulatory Compliance &amp; Standards Framework 5.7. ESG &amp; Sustainability Analysis 5.8. Disruption &amp; Risk Scenarios 5.9. Return on Investment &amp; Cost-Benefit Analysis 6. Cumulative Impact of Artificial Intelligence 2026 7. Leukapheresis Market, by Component 7.1. Introduction 7.2. Consumables 7.2.1. Anticoagulants 7.2.2. Kits 7.3. Equipment 7.3.1. Apheresis Systems 7.3.2. Monitoring Devices 8. Leukapheresis Market, by Disease Indication 8.1. Introduction 8.2. Autoimmune Diseases 8.2.1. Multiple Sclerosis 8.2.2. Rheumatoid Arthritis 8.3. Leukemia 8.4. Solid Tumors 9. Leukapheresis Market, by Technology 9.1. Introduction 9.2. Continuous Flow 9.3. Discontinuous Flow 10. Leukapheresis Market, by Application 10.1. Introduction 10.2. Diagnostic 10.2.1. Blood Analysis 10.2.2. Immune Monitoring 10.3. Research 10.3.1. Cellular Therapy 10.3.2. Stem Cell Research 10.4. Therapeutic 10.4.1. Autoimmune 10.4.2. Oncology 11. Leukapheresis Market, by End User 11.1. Introduction 11.2. Hospitals 11.3. Research Institutes 11.4. Specialty Clinics 12. Leukapheresis Market, by Region 12.1. Asia-Pacific 12.2. Europe 12.3. North America 12.4. Latin America 12.5. Africa 12.6. Middle East 13. Leukapheresis Market, by Group 13.1. NATO 13.2. G7 13.3. BRICS 13.4. European Union 13.5. ASEAN 13.6. GCC 14. Leukapheresis Market, by Country 14.1. China 14.2. United States 14.3. Japan 14.4. India 14.5. Germany 14.6. United Kingdom 14.7. Australia 14.8. France 14.9. South Korea 14.10. Italy 14.11. Canada 14.12. Russia 14.13. Brazil 14.14. Mexico 14.15. Spain 15. Competitive Landscape 15.1. Market Share Analysis, 2025 15.2. FPNV Positioning Matrix, 2025 15.3. Market Concentration Analysis, 2025 15.3.1. Concentration Ratio (CR) 15.3.2. Herfindahl Hirschman Index (HHI) 15.4. Recent Developments &amp; Impact Analysis, 2025 15.5. Product Portfolio Analysis, 2025 15.6. Benchmarking Analysis, 2025 16. Company Profiles 16.1. Allcells, LLC 16.2. Asahi Kasei Corporation 16.3. B. Braun Melsungen AG 16.4. Beijing Zksk Technology Co. Ltd. 16.5. Bioivt 16.6. Caltag Medsystems Limited 16.7. Charles River Laboratories International, Inc. 16.8. Danaher Corporation 16.9. Discovery Life Sciences 16.10. Fresenius Kabi AG 16.11. Guangzhou Daji Medical Science and Technology Co. Ltd. 16.12. Haemonetics Corporation 16.13. Intelligent Tissue Group 16.14. Lonza Group Ag 16.15. Macopharma SA 16.16. Medica Spa. 16.17. Miltenyi Biotec GmbH 16.18. Precision for Medicine, Inc. 16.19. Puriblood Medical Co. Ltd. 16.20. Stemexpress, LLC 16.21. Terumo BCT 16.22. Zenbio, Inc. For more information about this report visit <a href="https://www.researchandmarkets.com/report/leukapheresis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=8jz2jc&amp;utm_campaign=2308736+-+Global+Leukapheresis+Market+Growth+Accelerates+With+Cell+Therapy%2c+Oncology+and+Transplant+Demand&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/ds2l2s</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://ml.globenewswire.com/Resource/Download/a78aec95-7302-42c1-aa75-ea413510fdc5" title="Leukapheresis Market" rel="nofollow">Leukapheresis Market</a>
 </li>
 </ul>
<pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NzI2ZjI2YmMtZjhkZi00MzRmLWFlZjMtOGI3NzU0MTAwY2IwLTEwMjY3MzctMjAyNi0wNy0yMS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Global Leukapheresis Market Growth Accelerates With Cell Therapy, Oncology and Transplant Demand

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn